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Experiments on the P 388 D1 cell Line (48 h exposure) demonstrate that [ 1.2- 
bis-(fluomphenyl)ethylenediamine]platinum(II) complexes are comparably 
active on the. cell number and 3H-thynidine incorporation, irrespective of 
the position of the fluorine atom (ortho, meta, or para) and the nature of the 
“leaving group” (Cl- or H20). However, the. compounds of the R,R/S,S 
series are more active than those of the R,S series and comparable to cispla- 
tin. In the “tumor colony forming assay” the RNS.S configurated com- 
pounds are about ten times as active as cisplatin. The RJUS,S conligurated 
diaqua[l,2-bis(4-fluomphenyl)ethylenediamine]platinum(II) salts reach theii 
half maximum effect more readily (tin I 1.6 h) than their R,S configurated 
analogues (tin = 20 h). A time limited contact of the cells with W S , S  con- 
figurated d i ~ u a [ l , 2 - b i s ( 4 - f l u o m p ~ y l ) e ~ y l e n e d i ~ ] p l ~ ~ ( I I )  salts 
(-lh) leads to a similar inhibition like a permanent drug exposure indicating 
a fast uptake of the complex by the tumor cell. In experiments on the Ehrlich 
ascites tumor of the mouse and on the L 1210 leukemia cell line R,R/S,S- 
[ l , 2 - b i s ( 4 - f l u o r o p h e n y l ) e t h y l e ~ i ~ ] d i c ~ ~ p l ~ u m ( I ~  turns out to be 
equipotent with cisplatin 
Tumorhemmende [lfBs(fluorphenyl)etylendiamin]platin(II) Kom- 
plexe, 2. Teik Biologische Priifung - In vitro Studien an der P 388 D1 
Leukiimie Zellinie 
In Versuchen an der P 388 D1 Leukthie Zellinie (48 h Wirkstofiinkutation) 
wird gezeigt, das [ 1,2-Bis-(fluorphenyl)ethylendiamin]platin(II) Komplexe 
unabhhgig von der Stellung des Fluoratoms (ortho. meta oder para) und der 
Art der Abgangsgmppe (Cl- oder H20) eine vergleichbare Wirkung auf Zell- 
zahl und 3H-~ymidin-Einbau aufweisen Die Verbindungen der RJ/S.S- 
Reihe sind jedoch wirksamer a ls  die der R,S-Reihe und mit Cisplatin ver- 
gleichbar. Die Wirkung der R,R/S.S konligurierten Verbindungen liegt im 
“Tumor Colony Forming Assay” urn eine GrMenordnung iiber der des Cis- 
platin Der halbmaximale Effekt wird bei den R,R/S,S-konfigurierkn 
Diaqua[ 1,2-bis(4-fluorphenyl)ethylendiamin]platin(II)Salzen (tin = 1.6 h) 
erheblich schneller als bei ihren R,S-kontigurierten Analogen (tin P 20 h) 
eingestellt Em zeitlich limitierter Kontakt der Zellen mit RJUS,S-konfigu- 
rierten oiaqua[l,2-bis(~fluorphenyl)ethylendiamin]pl~(II)S~~ (-lh) 
liihrt zu M c h e n  Hemmwerten wie eine permanente Wirkstoffeinwirkung, 
ein Indiz fk eine schnelle Wirkstoffaufnahme. R,R/S.S-[1,2-Bis(4-fluorphe- 
nyl)ethylendiamin]dichlomplatin(II) erweist sich in Versuchen am Ehrlich 
Ascites Tumor der Maus und an der L 1210 Leukthie Zellinie als %quip 
tent mit Cisplatin. 
The antitumor activity of diastereomeric dichloro( 1,2-di- 
phenylethylenediamine)platinum(II) complexes is strongly 
influenced by substituents in para positions of both benzene 
rings. Among various residues fluorine proved to be of spe- 
cial interest’). The R,R/S,S configurated [1,2-bis(4-fluoro- 
pheny1)ethylenediaminel-dichloroplatinum(II) complex (15) 
was the most active. In part I of this publication we have 
described the synthesis of the diastereomeric ortho, meta 
and para fluoro substituted dichloro( 1,2diphenylethylene- 
diamine)platinum(II) complexes 13 to 18 and of their more 
water soluble diaquaplatinum(II) salts 25 to 32*). In part II 
of this publication we investigate the influence of the F-po- 
sition, the configuration and the leaving group (Cl- or H 2 0 )  
on the antitumor activity against P 388 leukemia in vitro. 
&) & Compd. 13 
14 
\ I 
HC -CH 15 
CI’ ’CI 
13 - 18 
Config. F-Position Abbreviation 
DJ- 2 D,L-2F-PtC12 
DJ- 3 D.L-3F-PtC12 
DJ- 4 D.L-4F-RC12 
meso 2 meso-2F-PtC12 
meso 3 mew-3F-PtClz 
meso 4 mew-4F-PtCl~ 
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25-32 
Results and Discussion 
x2- 
Compd. 
25 
26 
27 
28 
29 
30 
31 
32 
Config. 
DJ- 
DJ- 
DJ- 
meso 
meso 
meso 
D,L 
meso 
F-Pos. Counter Abbreviation 
Ion 
D,L-2F-PtS04 
D.L-3F-PtS04 
D,L-4F-PtS04 
meso-2F-PtSO4 
meso-3F-PtS04 
meso-4F-Pt SQ 
meso-4F-Pt(N03)2 
D,L-4F-Pt(NO3)2 
the position of the fluorine atoms. Generally, a stronger ac- 
tivity of the R,R/S,S diastereomers was observed, which are 
The experiments on the P 388 D1 leukemia cell line (48 h 
drug incubation) show that the identically configurated [1,2- 
bis(fluorophenyl)ethylenediamine]dichloroplatinum(II) 
complexes 13 to 18 and their diaquaplatinum(II) sulfates 
and nitrates 25 to 32 are comparably active in inhibiting cell 
proliferation and 3H-thymidine incorporation regardless of 
equiactive with cisplatin (Table 1). 
In addition to these experiments 13 to 18 were compara- 
tively tested with cisplatin in the in vitro soft agar tumor 
clonogenic assay (TCA) to determine their effect on the col- 
ony forming ability of P 388 D1 leukemia cells (i.e. the loss 
of their stem cell function in the presence of drugs). 
Tab. 1: Effect of Diastereomeric [ l,2-Bis(fluorophenyl)ethylenediamine]dichloroplantinum(II) Complexes and Diaqua-[ 1,2-bis(fluorophenyl)ethylene- 
diamine]platinum(II) Sulfates and Nitrates on 3H-Thymidine Incorporation and Cell Proliferation of P 388 DI Leukemia Cells, 48 h Drug Incubation. 
Conpound Cell Number 3H-Thymidine Incorp. 
(No) % T/C at EDm % TIC at EDm 
1.10-6 M [MI M [MI 
meso-2F-RS04 (28) 
meso-3F-PtS04 (29) 
meso-4F-PtSO4 (30) 
meso-4F-Pt(N03)~ (32) 
meso-2F-PtClz (16) 
meso-3F-PtClz (17) 
mesdF-PtCl2 (18) 
D.L-2F-PtS04 (25) 
D.L-3F-PtS04 (26) 
DJAF-PtS04 (27) 
DL-~F-P~(NO~)Z (31) 
D,L-2F-PtC12 (13) 
D,L3F-K12 (14) 
D.L-4F-PtClZ (15) 
Cisplatin 
93 
77 
88 
86 
69 
83 
90 
34 
32 
31 
23 
30 
31 
29 
2.6.10-6 
1.8.1 0-6 
3.8. 
3.8.10-6 
2.3.1 0-6 
4.1 
2.6.10'6 
4.3.10-7 
5.1 . 
5.4.10-7 
4.6.10-7 
2.0.10-7 
4.4.1 0-7 
4.3.10'7 
4.8.10-7 
92 
77 
84 
92 
75 
93 
91 
8 
26 
24 
8 
14 
23 
19 
2.6,10-6 
2.3.10" 
4.0. 
3.4.10-6 
2.2.10-6 
4.8.1 0-6 
3.4.10'6 
3.5.10-7 
6.5.1 0-7 
7.2.10-7 
5.9.10'7 
4.8.10-' 
4.9. 
5.5.10-7 
4.5.10'7 
Tab. 2: Antitumor Effect of Fluoro Substituted DicNoro-(l,2-diphenylethylenediamine)platinum(II) Complexes on the P 388 DI Leukemia Cell Line - 
Colony Forming Assay 
Compd. 
Colony Formation 
% Inhibition EDso (M) % Inhibition EDm (M) 
48 h Drug Exposure 1 h Drug Exposure 
at 10" M at 2 x M 
13 (D.L-2F-PtCIz) 100 2 x 10-8 
14 (D.L-3F-PtCIz) 98 5 x 10-8 
15 (DL-4F-PtC12) 96 5 x 10'8 
16 (meso-2F-PtClz) 49 1 x 10-6 
17 (meso-3F-RClz) 9 4 x 10-6 
18 (meSO-4F-PtClz) 7 3 x 10-6 
Cisplatin 97 2 x 10-7 
60 
12 
70 
21 
18 
0 
30 
1 x 10" 
9 10-7 
1 x 10-6 
5 x 10-6 
8 x 
6 x 
3 10-5 
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Stem cells (e.g. the hematopoietic stem cell), which are re- 
sponsible for maintaining the integrity and continued survi- 
val of any particular cell population, are capable of an in- 
definite number of divisions. Unlike to this the differen- 
tiated cells lack this unlimited capacity of proliferation3). In 
accordance with the stem cell conception it is assumed that 
in cancer diseases so called tumor stem cells are responsible 
for tumor growth or regrowth after treatment and also for 
the forming of metastases. Therefore, it is the tumor stem 
cell population that must be eradicated to obtain curative 
cancer chemotherapy4). Clonogenic tumor cells in TCA are 
considered to be closely related to tumor stem cells in situ, 
therefore, the predictive value of this assay for a possible in 
vivo activity should be superior to other in vitro assays. 
In the TCA, too, the R,R/S,S configurated compounds 13 
to 15 as well as the R,S configurated compounds 16 to 18 
proved to be equiactive on the P 388 D1 leukemia cell line 
irrespective of the position of the fluorine atoms in the phe- 
nyl rings. However, the compounds of the R,R/S,S series 
are much more active than those of the R,S series. Drug in- 
cubation periods of 48 h produced stronger inhibition ef- 
fects than those of 1 h. EDSO-values of the R/S configurated 
compounds 16 to 18 are comparable to those listed in table 
1. It is of interest that the EDSO-values of the R,R/S,S con- 
figurated compounds 13 to 15 after 48 h drug exposure are 
one order of magnitude smaller than those achieved in cell 
culture experiments (see Table 1 and 2). In the TCA com- 
pounds 13 to 15 turned out to be markedly superior to cis- 
platin. 
Tab. 3: Effect of Diastereomeric [ 1,2-Bis(4-fluorophenyl)ethylene- 
diamine]dichloroplatinum(II) Complexes and Diaqua-[ 1.2-bis(4-fluoro- 
phe.nyl)ethylenediamine]platinum(II) Sulfates and Nitrates (1 M) on 
3H-Thymidine Incorportation and Viability of P 388 DI Leukemia Cells. 
~~ ~ ~~ ~ ~~ 
Compound Incubation % T/C % Viability, 
(No) Time [h] 
meso4F-Pt(N03)2 
(32) 
1.5 
2.0 
1 .o 
2.0 
1 .o 
2.0 
10.2 
14 
18 
24 
34.3 
48 
10.2 
14 
18 
24 
34.3 
48 
89.2 
69.2 
83.5 
55.3 
63.4 
42.6 
88.3 
71.4 
63.9 
23.5 
14.4 
3.2 
75.9 
63.3 
45.5 
17.5 
10.3 
2.1 
98.3 
98.5 
98.5 
98.8 
95.0 
97.5 
97.5 
97.5 
97.0 
96.0 
96.3 
96.0 
95.5 
97.5 
97.0 
96.0 
93.5 
96.8 
: determined by trypan blue exclusion staining 
Platinum(II) complexes cause a slowed DNA synthesis 
phase and a transient G2 arrest at low drug concentrations, 
as shown with cisplatin. However, at higher concentrations 
an irreversible Gz arrest associated with extensive chrome 
some damage takes place. This is accompanied by a loss of 
viability (visible by trypan blue staining), which is detect- 
able 4 days after short drug incubation (2 h) and reaches its 
maximum after 7 days5). 
In the case of the R,R/S,S configurated [1,2-bis(4-fluoro- 
phenyl)ethylenediamine]platinum(II) complexes 15.27, and 
31 we found no loss of viability of P 388 D1 cells (drug ex- 
posure: 2 h, table 3). Under the same experimental condi- 
tions the 3H-thymidine incorporation was reduced at about 
50 %. 
Tumor cells which had been treated with the R,S config- 
urated compounds 30 and 31 were viable even after 48 h of 
exposure (table 3). Perhaps the loss of cell membrane inte- 
grity (a sign for cell death) is a longer, time dependent pro- 
cess which requires 4 to 8 days as shown in the cisplatin ex- 
perimen?). Also in the TCA, (indicative for cell death, too), 
the R,S-[ 1,2-bis(4-fluorophenyl)ethylenediamine]platinum 
(II) complex was only slightly active (7 % inhibition at lo4 
M and 48 h exposure; table 2). The R,R/S,S-[ 1,2-bis(rlfluo- 
rophenyl)ethylenediamine]platinum@) complex, however, 
leads to a marked reduction of colony numbers (96 % in- 
hibition at M and 48 h exposure; 70 % inhibition at 2 x 
M and 1 h exposure; table 2). Therefore, a longer ob 
servation time (compare also table 4) should also lead to a 
corresponding portion of non-viable cells in the trypan blue 
exclusion test. 
The cytotoxic effect of platinum complexes is not the re- 
sult of an inhibition of the DNA synthesis in the S phase of 
the cell cycle (up to now generally accepted as the critical 
step in cisplatin-induced toxicity) but of a persistent (i.e. ir- 
reversible) G2 arrest, as shown by Eusrman and Soremod). 
Furtheron it is proposed that the G2 arrest results from the 
inability of the cells to transcribe genes required for the pas- 
sage into mitosis6). 
The lack of differences in activity between analogous cis- 
PtA2C12 and cis[PtA2(H20)2]X complexes (A5 1,2-bis (2- 
,3-, and 4-fluoropheny1)ethylenediamine; X: S042- or 2 
NO3-) is surprising since, as a rule, the change from the non- 
ionic dichloroplatinum(lI) complex to the ionic diaquaplati- 
num(II) complex leads to a decrease in antitumor activity. 
An example for a drastic change of efficacy is provided by 
cis-F’t(NH3)2C12 in which the substitution of C1 by H20 is 
accompanied by a loss of activity on the L 1210 leukemia of 
the mouse7). In contrast to this, diaquaplatinum(II) com- 
plexes with spacious, lipophilic ligands like cis-[Pt(DAC) 
(H20)2] (NO3)* (DAC: 1,2-diaminocyclohexane) show 
tumor inhibiting properities (L 1210 leukemia, mouse) 
which are comparable to those of the analogous dichloro- 
platinum(II) complexes7). 
In these complexes presumably two factors are respon- 
sible for the appearance of antitumor activity: 
1. The steric shielding of Pt. It impedes the reaction with 
bionucleophils. Therefore, the inactivation of the 
complex during its transport to the tumor cell is retar- 
ded. 
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2. The hydrophobic character. It facilitates the penetration 
of the drug across the plasma membrane of the tumor 
cell. 
Both factors lead to therapeutically active drug levels in 
the tumor cell. 
According to the rate of hydrolysis, two classes of plati- 
num@) complexes can be observed 
Class 1 complexes in which the leaving group is immedi- 
ately substituted by HzO (e.g. [c~s-P~Az(HzO)(SO~)].HZO in 
which the SO4 ligand is bonded to the Pt through one of its 
oxygen atoms; regarding to the coordination of SO4 to Pt 
see below). 
Class 2 complexes, in which the exchange of the leaving 
group for HzO takes 1 to several h (e.g. cis-PtAzClz). 
Compounds of class 1, e.g. 30, are - as mentioned - only 
antitumor active, if their amine ligand causes a steric shield- 
ing of pt, thereby hindering the reaction with bionucleophils 
during the transport to the tumor cell. Unlike to this, com- 
pounds of class 2 are also antitumor active, if they contain 
small amine ligands like N H 3 .  Class 2 complexes are weak- 
ly-reactive prodrugs which are slowly hydrolized into the 
active drugs (cis[PtA~(H20)2]~+). Therefore, the inactivation 
of class 2 complexes by bionucleophils is impeded during 
the transport to the tumor cell. They probably pass the cell 
membrane in the form of non-ionic cis-PtAzX, followed by 
an activation in the cell (e.g. exchange of X by Hz0). In the 
case of cisplatin hydrolysis is supposed to be suppressed 
under the conditions of the high extracellular C1- concentra- 
tion (0.103 M), while the low C1- level (0.004 M) in the cy- 
toplasm facilitates the Cl-/I-IzO exchange. 
These findings infer that the kinetic behavior of plati- 
num@) complexes in the reaction with nucleophils is essen- 
tial for the antitumor activity, therefore, too fast or too slow- 
ly reacting complexes are weakly active. 
We think that the development of water soluble and hence 
therapeutically better applicable platinum(I1) complexes 
with [ci~-PtA~(H20)2]X structure is feasible. This requires 
the choice of appropriate amine ligands which do retard the 
inactivation of the drug via reaction with bionucleophils 
during the transport to the tumor cell but still allow the in- 
teraction with DNA, which is essential for the antitumor ac- 
tivity. 
In the following we describe the influence of the leaving 
group (HzO or Cl-) and the configuration of C-1 and C-2 of 
the 1,2-bis(4-fluorophenyl)ethylenediamine ligand on the 
time-dependent inhibition of the 3H-thymidine incorpora- 
tion in the P 388 D1 leukemia cell culture. 
In the R,R/S,S confgurated series a considerably faster 
onset of action of the equally active diaquaplatinum(II) sul- 
fate (27) and nitrate (31), tln G 1.6 h (time (h) required for a 
50 9% inhibition), is observed compared to dichloroplati- 
num@)-compound 15, tln G 3.3 h, (Figure 1). This dif- 
ference is caused by a slow hydrolysis of 15 to f o m  the ac- 
tive species [cis-PtAz(HzO)2]X, which is responsible for the 
reaction with DNA. 
In the case of 31, whose nitrate residues are directly coor- 
dinated with R2+, an exchange of NO3 by H20 takes place 
% T/C 
2 0- 
10- 
0 
I I I I I I 
1 2 3 4 5 6  
Incubation time [h] 
Figure 1: Influence of the Leaving Group (H20 or Cl') of [D.L-1,2-Bis(4- 
fluorophenyl)ethylenediamine]platinum(II) Complexes on the Time-De- 
pendent Inhibition of the 'H-Thymidin Incorporation in the P 388 D1 Leu- 
kemia Cell Culture. Drug Concentration: l.10-5 M. Compounds: + 15 
(D,L-4F-PtC12), + 27 (D,L4F-PtS04), + 31 (D.L4F-Pt(N@)2). Additio- 
nal values for 15: 13.25 h I 26 % TIC; 22.25 h 1 5 % TIC; 30.1 h I1 % TIC; 
48h/I%T/C.  
1 0 0  
0 
1 0  2 0  30  4 0  50 
Incubatlon time [h]  
Figure 2: Influence of the Leaving Group (HzO or Cl-) of [meso-l,2-Bis(4- 
fluorophenyl)ethylenediaminelplatinum(II) Complexes on the Time-De- 
pendent Inhibition of the 3H-Thymidine Incorporation in the P 388 D1 Leu- 
kemia Cell Cultwe. Drug Concentrations: L ~ O - ~  M. Compounds: 4 18 
(meso-4F-PtCI2),~ 30 (rneso4F-PtS04)~32 (meso-4F-Pt(N03)2) 
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2-  so4 
Formula IIIa and IIIb 
immediately after dissolution in water. The same is true for 
a sulfate residue in compound 27 which is coordinated with 
Pt. 
According to the elemental analysis, 27 contains two 
molecules of wate?). Besides the structural formula IIIa, 
structure IIIb (unidentate complex) must be discussed (see 
also Part I of this publication). 
A compound of type IIIb (structurally analogous to 27) 
was obtained by Rochon and Melanson8) by the reaction of 
(N,N’-dimethylethylenediamine)diiodoplatinum(II) with 
AgzS04. The structure of [aqua(N,N’-dimethylethylene- 
diamine)sulfatoplatinum(II)]hydrate was confirmed by X- 
ray analysis8). In this molecule the coordinated water forms 
two strong hydrogen bonds, donating one proton to an 
oxygen atom of the sulfate ligand and the other proton to the 
lattice water oxygen. The relationship between the HzO 
molecules and the sulfate residue contributes to complex 
stability. 
The question whether 27 is described by formula IIIa or 
IIIb is of no importance for the inhibition kinetics of the 3H 
thymidine incorporation into DNA. In water the sulfato 
residue of the unidentate sulfatoplatinum(II) complex IIIb 
is quickly replaced by HzO molecules, forming the diamine- 
diaquaplatinum(II) ion IIIa. This was proved by us in the 
case of the analogous compound aqua[meso- 1,2-bis(2,6-di- 
chloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum 
(11) by an increase in conductance to a constant level within 
a few min after dissolution of the compound in watep). 
In contrast to the R,R/S,S configurated complexes the 
time-dependent inhibition of the 3H-thymidine incorpora- 
tion by the R,S configurated complexes 18, 30, and 32 is 
not contingent on the nature of the leaving group (HzO or 
C1-) as shown by the tin-values (20 h) (Figure 2). 
The great differences between the tin-values of R,R/S,S 
and R,S configurated complexes can be explained by a 
stronger steric hindrance caused by the axially standing phe- 
nyl ring of the latter complexes impeding the approach to 
DNA, as has been discussed elsewhexdo.”). In the case of 
the R,R/S,S configurated complexes only the conformation 
is favored in which both phenyl rings are equatorially ar- 
ranged2). 
Accordingly, different kinetics have been reported for the 
reactions of the diastereomeric [ 1,2-bis(4-fluorophe- 
nyl)ethylenediamine]sulfatoplatinum(II) complexes 27 and 
30 with salmon testis DNA13). In these experiments, DNA 
synthesis catalysed by E. coli-DNA polymerase I was in- 
hibited by the coordination reaction of the platinum(II) 
complexes with DNA, presumably in N-7 positions of 
guanines. The kinetics of inhibition followed the formation 
of monoadducts, and was faster in the case of the racemate 
27 than of the meso-form 30. 
Tab. 4: Long-Term Effect of [ 1,2-Bis(4-fluorophenyl)ethylenediamine] 
platinum(1I) Complexes (1 x lO”M) on the 3H-Thymidine Incorporation 
in P 388 DI Leukemia Cells after Short Drug Incubation Times 
Compound 3H-Thymidine Incorporation 
(No) % TIC‘ % TICb 
~~ 
DL-4F-PtC12 1.5 h : 87.9 1.5 hc/4 hd : 73.7 
(15) 2 h : 69.2 2 h I 4  h : 63.4 
4 h : 39.4 
D.L-4F-PtS04 1 h : 82.6 1 h 13 h : 45.4 
(27) 1 h I6  h : 22.8 
2 h : 51.9 2 h 1 3  h : 36.0 
2 h / 6 h  : 19.3 
3 h : 16.7 
6 h : 6.4 
D,L-4F-Pt( NOs)z 1 h : 63.4 1 h / 6 h  : 21.0 
(31) 6 h : 4.6 
a : % TIC- values for continues treatment (SD 5 14 %) 
b : Q TIC- values from the wash-out experiments (SD 5 14 %) 
c: Time of drug exposure 
d: total incubation time (drug exposure plus incubation in drug-free me- 
dium) 
Experiments in which P 388 D1 leukemia cells were ex- 
posed to the [ 1,2-bis(4-fluorophenyl)ethylenediamine]plati- 
num(II) comlexes 15, 27, and 31 for a short time, washed 
and reincubated with drug-free medium (Table 4). hint at 
possible differences in the uptake of ionic and non-ionic 
species by the tumor cells. 
While the dichloroplatinum@) complex 15 yields only a 
moderate further decrease in DNA synthesis during the 
reincubation, a strong effect is observed in the case of the 
diaquaplatinum(II) complexes 27 and 31. This finding could 
be explained by a higher intracellular concentration caused 
by a faster uptake of the ionic diaquaplatinum(II) com- 
plexes 27 and 31 by the tumor cells compared to the non- 
ionic dichloroplatinum@) complex El4).  This is even more 
surprising since an inactivation of the reactive 
diaquaplatinum(II) species by nucleophils in the medium 
must be expected. With the dichloroplatinum(II) species 
this inactivation process is only possible after hydrolysis. 
Apparently, the reaction of 27 and 31 with nucleophils is 
strongly retarded due to steric conditions. It may also be 
that distinct mechanisms are responsible for the permeation 
of cisplatin and [ 1,2-bis(4-fluorophenyl)ethylenediamine]- 
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diaquaplatinum(II) complexes across the cell membrane. 
Such differences can be the basis of an activity of the [1,2- 
bis(4-fluorophenyl)ethylenediamine]platinum(II) complexes 
against cisplatin-resistant tumors, as is pointed out in the 
following. 
The development of resistance toward cisplatin as a result 
of alterations in drug accumulation has been di~cussed’~). 
Although it is widely accepted that platinum(II) complexes 
enter the cell by diffusion along a concentration gradient’@, 
there is evidence that the transport of cisplatin is carrier 
mediated. Byfield and Cal~bro-Jones’~~’~) demonstrated that 
amino acids protect cells against cisplatin, suggesting that 
the latter is also taken up by an amino acid transport 
mechanism. 
The resistance to cisplatin could stem from somatic muta- 
tions that yield cells whose membrane carriers are either 
fewer in number or have reduced drug affinity17). These al- 
terations lead to a minor trans-membrane transport. Hints at 
this mechanism of resistance are given by uptake experi- 
ments with a L 1210 leukemia cell line which show a 6.6 
fold resistance to cisplatin. They demonstrated a decreased 
accumulation of cisplatin in the cells”). The observation 
that a L 1210 leukemia cell line primarily resistant to mel- 
phalan is cross-resistant to cisplatin supports also this mode 
of action, since the melphalan resistance was accompanied 
by a decrease in the melphalan concentration within the 
cells’’). 
Because of the suggested differences between cisplatin 
and the diaquaplatinum(II)complexes 27 and 31 concerning 
the mechanism of their trans-membrane transport, an effect 
of these new complexes against cisplatin resistant tumors is 
conceivable. An indication of such a therapeutic applica- 
bility is the finding that of mice bearing cisplatin-resistant 
Ehrlich ascites tumors about 70 % are cured by [R,R/S,S- 
1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum 
@I) (3 x 5 m@g ip), a substance which is structurally re- 
lated to 27 and 31 (Seeber, unpublished). Compounds 27 
and 31 might be “carrier-independent” platinum complexes, 
which penetrate the tumor cell membrane by simple diffu- 
sion. “Carrier-independent” drugs are of therapeutic interest 
since: 1. they show a reduced tendency to induce 
resistance”) and a high antitumor activity in vivoZ2) and 2. 
they are known to lack cross-resistance to “carrier-depend- 
ent” platinum(II) complexes like ~ isp la t in’~*~~)) ,  Treatment 
schedules in which such “carrier-independent” platinum(II) 
complexes are combined with cisplatin or another “carrier- 
dependent” platinum@) complex are predicted to be most 
useful, as they would minimize the outgrowth of drug-resis- 
tant tumors and, therefore, should elongate the remission 
period. 
In order to verify the lack of cross resistance to cisplatin 
the R,R/S,S configurated [ 1,2-bis(fluorophenyl)ethylene- 
diaminel-platinum(II) complexes 13 to 15 were evaluated 
on the cisplatin-sensitive and -resistant Ehrlich ascites 
tumor of the mouse. Compounds 13 and 14 were inactive on 
the cisplatin-sensitive Ehrlich ascites tumor at a dose of 3 x 
10 mg/kg and 3 x 20 mgkg (Figures 3 and 4). Complex 15, 
however, cured 80 % of the animals at a dose of 3 x 10 
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Figure 3: Effect of 13 (2-F; R,R/S,S), 14 (3-F; R,R/S,S) and 15 (4-F; 
R,R/S,S) on Cisplatin-sensible Ehrlich Ascites Tumor of the Mouse; 3 x 10 
m a g :  13 ----; 14 -o-o-; 15 -oo-oo-oo.; Control ~ 
10 20 30 Days 
Figure 4 Effect of 13 (2-F; R,R/S,S), 14 ( 3 3  R,R/S,S) and 15 (4-F. 
R,R/S,S) on Cisplatin-sensible Ehrlich Ascites Tumor of the Mouse; 3 x 20 
m a g :  13 ----; 14 -o-o-; 15 -oo-oo-; Control ___ 
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Figure 5: Effect of 15 (4-F; R,R/S,S) on Cisplatin-resistant Ehrlich Ascites 
Tumor of the Mouse; 3 x 10 m a g  ----; 3 x 20 m@kg -0-0-0-; 3 x 50 m a g  
-oo-oo-oo-; C o n u o l ~  
m a g  (Figure 3). After the elevated dosage of 3 x 20 m a g  
15 all animals were disease-free (Figure 4). On the 
cisplatin-resistant Ehrlich Ascites tumor however, 15 was 
inactive even at an extremely high dosage (Figure 5). 
In figure 6 a comparative test with cisplatin on this resis- 
tant tumor model is shown. 
Compound 15 was also tested on various L 1210 leukemia 
cell lines which possess resistance against platinum 
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Figure 6 Effect of Cisplatin on a resistant Ehrlich Ascites Tumor of the 
Mouse; 6 m a g  ----; 8 m a g  -*-*-*-; 12 m a g  -**-**-**-; Control - 
complexes. These cell lines have been developed by East- 
man et. al?*-’’). Against the wild type of the L 1210 cell 
line, 15 showed an ED50 value (0.2 p M) which is com- 
parable to that of cisplatin ED50 (p M) = 0.3). In contrast to 
the results on the cisplatin-resistant Ehrlich ascites tumor 
(Figure 5),15 caused a marked effect on a L 1210 cell line, 
which is 100 fold resistant to cisplatin. The determined 
ED50 value of 1,4 (pM) corresponds only to a 7 fold resist- 
ance. However, a surprisingly high resistance against 15 
(ED50 (pM = 37, corresponding to a 185 fold resistance) 
was found in a DAC-resistant L 1210 cell line. This line is 
about 40 fold resistant to DAC-Pt(II) complexes. This sug- 
gests that 15 is closer related to DAC-Pt(II) complexes than 
to cisplatin regarding its mode of action. 
The resistance of the above described new L 1210 cell 
lines against platinum(II) complexes has in part been at- 
tributed to an enhanced repair of DNA-Pt-le~ions’~.~~). 
However, reduced drug accumulation also seems to play a 
role. In this connection it is also worthy of note that the 
DAC resistant L 1210 cells exhibit a pronounced reduction 
in accumulation of (1,2-diaminocyclohexanene)platinum(II) 
complexes28). This feature may be an important factor in the 
low sensibility of the DAC resistant L 1210 cell line against 
15. 
These and other results2’) in the class of (1,2-&phenyle- 
thylenediamine)platinum(II) complexes show that the activ- 
ity against cisplatin-resistant tumors depends on the nature 
and position of the ring substituents and also of the ligand 
configuration. 
In further publications we well inform on the development 
of new platinum complexes for the second line therapy of 
tumor diseases after development of resistance against cis- 
platin. 
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Experimental Part 
P 388 Dl Leukemia cell culture experiments 
Standard conditions. The P 388 DI cells (ATCC CCL 46) were grown in 
static suspension culture in RPMI 1640 medium (Gibco) supplement with 
10 % heat-inactivated horse serum (Boehringer), 10 mM HEPES buffer 
(Biochrom), 2 mM glutamine (Biochrom) and NaHC03 (0.85 @) in a 
humidified atmosphere of 5 % COz in air at 37’C. Stock cultures were 
grown in 75 cm2 culture flasks (Falcon). The diaquaplatinum(I1) comple- 
xes were dissolved in bidistilled water or methanol, the dichloroplati- 
num(I1) complexes in DMF. The test compounds were added as 5MT or 
1000-fold concentrated stock solutions. 
Determination of EDSo 
2 ml of cell suspension (7-8.104 cells/ml) were placed in glass centrifuge 
tubes sealed with aluminium caps and incubated under standard conditions. 
After 4 h incubation cells were counted with a Coulter Counter (Coulter 
Electronics Ldt) and the test compounds were added. 2 h prior to the end of 
the experiment the cells were labeled with 0.3 pCi 3H-thymidine (40-60 
Ci/mmol, New England Nuclear) per tube. After 48 h 0.5 ml of culture 
were used to determine cell numbers, the remaining portion was 
centrifuged and washed twice with ice-cold PBS (Phosphate buffered 
saline: NaCl (8 g), KCl (0.2 8). NazHPO~HzO (0.15 g) and KHzP04 (0.2 
g) in 1 L of HzO). The pellet was resuspended in 1 ml water and the cells 
were broken up by sonication using a Branson sonifier. To the sonicated 
cells 4 ml 10 9% TCA was added and the precipitate was filtered over 0.45 
pm filter (Sartorius). The ’H-thymidine incorporation was determined in 
10 ml Quickszint 212 (Zinsser Analytik) in a Beckman LS 1801 liquid 
scintillation counter. % T/C of cell growth was calculated according to (T- 
Z) lOO/(C-Z) ( T  cell number of treated cell culture at the end of i n c u b  
tion, C cell number of untreated cell culture at the end of incubation, 2: 
cell number at the beginning of incubation). 
Time-dependent of inhibition of ’H-thymidine incorporation 
Cell suspension (2 ml) were placed in glass centrifuge tubes sealed with 
aluminium caps. For incubation times up to 6 h the initial cell concentra- 
tion was 2.4-2.6 . 1 6  cells/ml. When cell cultures were incubated up to 48 
h the initial cell number per ml was 1.1-1.4.16. The test compounds were 
added in a final concentration of l.10-5 M and 20 min prior to the end of 
the experiment the cells were labeled with 1 pCi 3H-thymidine per tube. 
The 3H-thymidine incorporation was stopped rapidly by shaking the tubes 
in ice water. The 3H-thymidine was determined as described above. For % 
T/C calculation control cultures were treated identically. 
Long term effect on the 3H-thymidine incorporation afer short drug 
incubation times 
Cells were incubated with test compounds for varying periods of time 
and spun down at 500 g. The pellet was washed with medium and the cells 
were resuspended and reincubated in drug-free culture medium. The %I- 
thymidine labeling procedure was performed as described above. 
Count of viable cell?4’ 
The number of viable cells was determined by means of trypan blue ex- 
clusion staining. Technique: wan blue stock solution (Sigma) was diluted 
with PBS to an end concentration of 0.16 %. Equal volumes of diluted stain 
and cell suspension were mixed. The number of cells not being stained 
(viable cells) was determined microscopically by means of a Neubauer he- 
matocytometer. 
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Tumor colony forming assay (TCA)”) 
Drug treatmentfor I h. The P 388 D1 leukemia cells (3 x lo4 viable cells 
fo a culture in asynchronous exponential growth) were incubated in 3 ml 
RPMI 1640 (Biochrom) supplemented with NaHC03 (0.85 gil; Merck). 
HEPES (10 mM. Biochrom), 10 % heat inactivated horse serum (Bio- 
chrom) and glutamine (2 mM, Biochrom) for 1 h with several drug concen- 
trations (addition as stock solution in HzO or DMF). Previous experiments 
had shown that the DMF itself in final concentration of 0.1 % does not 
inhibit the growth of the tumor cells. Than the cells were speparated by 
centrifugation, washed out and suspended in 3 ml upperlayer. 
Drug trearmentfor 48 h. The volume which contains 3 x lo4 cells was 
determined in the control. This volume was used as inoculum as well for 
the control as for the test. Further conditions c. f. 1 h experiments. 
Reile and coworkers 
References 
SOB agar cloning method 
With slight modifications, the clonogenic assay was performed according 
to Hamburger and Salomnz’. Briefly, the tumor cells were suspended in 
upperlayer consisting of 0.3 8 agar in enriched CMRL 1066 (Gibco) supp- 
lemented with 15 96 heat inactivated fetal calf serum (FCS; Boehringer), 
penicillin (final concentration 100 U/ml), streptomycin (100 pg)ml). gluta- 
mine (2 mM), CaClz (4 mM), ascorbic acid (0.3 mM), bovine insulin (2 
Urn),  asparagine (0.5 mM) and mercaptoethanol (50 pM; the latter sub- 
stances all obtained from Sigma). 1 ml of the resultant mixture was pipetted 
onto 1 ml underlayer in plastic petri dishes (Falcon plastics); this was done 
in triplicate for each of at least 3 different drug concentrations. The under- 
layer consisted of 0.5 % agar in enriched McCoy’s 5A medium (Gibco) 
supplemented with 15 % FCS. Napyruvate (final concentration 2 mM); L- 
serine (0.4 mM), glutamine (2 mM), penicillin (100 U/ml), streptomycin 
(100 pg/ml), tryptic soy broth [ O S  % (w/v)] and asparagine (0.75 mM, the 
latter substances all obtained from Sigma). The plates were incubated at 
37’C in an atmosphere of 5 8 COz and 100 % humidity, after microscopi- 
cal control had confirmed that there were no artificial cell-aggregates. The 
number of tumor cell colonies (aggregates of more than 32 cells) was 
counted 10-14 days after plating by means of an inverted microscope. Drug 
effects were expressed as the percentage of inhibition of colony formation 
compared to the untreated dishes. 
Ehrlich Ascites Tumos6’ 
The different resistant Ehrlich ascites tumor lines (wild type and Cispla- 
tin-resistant) are maintained by routine passage in female NMRI mice. For 
the evaluation of the therapeutic activity groups of ten female mice were 
inoculated in with 10‘ cells. On the following 3 days the animals received 
ip injections of either platinum complex suspended in polyethylene glycol 
4oo/HzO 1: 1 or of polyethylene glycol W/H20 1:l alone for control. 
L I210 Leukemia cell culture experiments. 
Sensitive and resistant L 1210 cells have been developed and described 
by Eastman et al?8’29). 
Suspension cultures are grown in McCoy’s 5a (modified) medium sup- 
plemented with NaHCO3 (2.2 u), penicillin (250 U/ml), streptomycin 
(250 U/ml). fungizone (1pg)ml) and 16 % calf serum. For growth inhibition 
4 ml of cell suspension (approximately 5 x lo4 cells/ml) were incubated in 
triplicate with varying concentrations of drug over a 3-day period. The drug 
was added as a loo0 fold stock solution in DMF or DMSO. Stock solutions 
especially DMSO solutions were kept no longer than 5-10 min. After 3 
days 1 ml aliquots were counted on a Coulter counter and ED50 values were 
determined. 
1 
2 
M. Jennenvein, B. Wappes, R. Gust, H. Schonenberger. J. Engel, S. 
Seeber, and R. Osieka, J. Cancer Res. CLin Oncol. II4.347 (1988). 
R. Miiller. R. Gust, M. Jennenvein, H. Reile, R. Laske, W. Krischke, 
G. Bemhardt. Th. SpruS. J. Engel. and H. Schonenberger, Eur. J. Med. 
Chem. 24,341 (1989). 
B.T. Hill, Biochemical and Cell Kinetic Aspects of Drug Resistance. 
In: Drug and Hormone Resistance in Neoplasia, N. Bruchovsky, and 
J.H. Goldie, (Eds.), p. 2 1 4 ,  CRC Press Inc., Boca Raton. Florida, 
1982. 
G.G. Steel, Growth and Survival of Tumor Stem Cells. In. Growth Ki- 
netics of Tumors, G.G. Steel (Ed.), p. 217-262, Oxford University 
Press, Oxford 1977. 
Ch. M. Sorenson and A. Eastman, Cancer Res. 48.4484 (1988). 
Ch. M. Sorenson and A. Eastman, Cancer Res. 48,6703 (1988). 
J.P. Macquet and J.J. Butour, J. Nat. Cancer Inst. 70,899 (1983). 
D. Rochon and R. Melanson, Inorg. Chem. 26,989 (1987). 
J. Karl. R. Gust, Th. Spru6. M.R. Schneider, H. Schonenberger, J. 
Engel, J.H. Wrobel, F. Lux, and S. Trebert-Haeberlin. J. Med. Chem. 
31.72 (1988). 
10 B. Wappes. M. Jennerwein. E. von Angerer, J. Engel, H. Schonenber- 
ger, H. Brunner. M. Schmidt, M. Berger, D. Schmihl, and S. Seeber, J. 
Cancer Res. Clin. Oncol. 107,15 (1984). 
11 B. Wappes. M. Jennenvein. E. von Angerer, H. Schonenberger, J. 
Engel, M. Berger, and K.H. Wrobel. J. Med. Chem. 27,1280(1984). 
12 H. Schonenberger, R. Gust, J. Karl, Th. SpruS, M.R. Schneider, R. 
Hartmann, Ch. Batzl, S. Schertl. J. Engel, F. Lux, and S. Trebert-Hae- 
berlin: Rezeptorgebundene Chemorherapie in “Antitistrogene in For- 
schung und Klinik”, Herausgeber: H.G. Meerpohl, M. Kaufmann, D. 
Alt und A. Pfeiderer, Zuckschwerdt Verlag, Miinchen 1989. 
13 W. Schaller, H. Reisner und E. Holler. Biochemistry 26,943 (1987). 
14 Further studies using radiolabelled complexes me planned to elucidate 
the uptake and subcellular distribution. 
15 As further possible mechanisms of resistance. Eastman and RichonZ3’ 
discuss deviations in intracellular inactivation of platinum compounds, 
in DNA repair, and in the capacity to tolerate high levels of DNA pla- 
tination. 
16 S.K. Mauldin, J. Husain, A. Sancar, and S.G. Chaney, Cancer Res. 46, 
2876 (1986). 
17 J.E. Byfield and P.M. Calabro-Jones, Nature294.281 (1981). 
18 J.E. Byfield and P.M. Calabro-Jones, Roc. Am. Ass. Cancer Res. 22, 
229 (1981). 
19 W.R. Waud and S.R. Blount, Roc. Am. Ass. Cancer Res. 26. 260 
(1985). 
20 W.R. Redwood and M. Colvin, Cancer Res. 40,1144 (1980). 
21 F.M. Schabel Jr., M.W. Trafer, W.R. Laster, Jr.; G.P. Wheeler, and 
M.H. Win, Antibiotics Chemother. 23,200 (1978). 
22 F.M. Schabel. Jr.. Cancer Treat. Rep. 60,665 (1976). 
23 A. Eastman and V.M. Richon, In “Biochemical Mechaaisms of Plati- 
num Antitumor Drugs”, D.C.H. Mc Brien and T.F. Slater. Eds., p 91, 
IRL Press, Oxford, Washington DC 1986. 
24 Lee Eng-Ihang-HuangKuo-Hsiung, C. Piantadosi, T.A. Geissman, and 
J.S. Pagano, J. Pharm. Sci. 61,1960(1972). 
25 A. Hamburger and S.E. Salmon, J. Clin. Invest. 60,846 (1977). 
26 S. Seeber, R. Osieka, C.G. Schmidt, W. Achterrath, and S.T. Crooke, 
CancerRes.42,4719(1982). 
27 M. Jennerwein, R. Gust, R. Miiller, H. Schonenberger, J. Engel, MR. 
Berger, D. Schmiihl, S. k b e r ,  R. Osieka, G. Atassi, and P. Markhal- 
De Bock, Arch. Pharm. (Weinheim) 322,25 (1989); 322.67 (1989). 
28 A. Eastman and S. Ulenye, Cancer Treat. Rep. 68,1189 (1984). 
29 V.M. Richond. N. Schulte. and A. Eastman. Cancer Res. 47. 2056 
(1987). 
30 A. Eastman and E. Bresnick, Biochem. Pharmacol. 30,2721 (1981). 
31 N Sheibani, M. Jennenvein. and A. Eastman, Biochemistry 28. 3126 
(1989). 
32 A. Eastman and N. Schulte, Biochemistry 27,4730 (1988). 
3 
4 
5 
6 
7 
8 
9 
[Ph642] 
Arch. Pharm. (Weinheim) 323, 133-140 (1990) 
